ProtoKinetix,
Incorporated (OTC: PKTX) (the "Company" or "Protokinetix") (www.protokinetix.com)
is pleased to announce that it has completed a private placement (the
“Offering”) for gross proceeds of $125,000. The Company has issued
2,500,000 shares of common stock at a price of $0.05 per share. One of
the purchasers under the Offering is the President and Chief Executive
Officer of the Company, Clarence E. Smith, who invested $75,000 for the
purchase of 1,500,000 shares of common stock of the Company.
The securities offered pursuant to the Offering will not be registered
under the United States Securities Act of 1933 (the “Securities Act”)
and may not be offered or sold in the United States absent registration
or an applicable exemption from the registration requirements of the
Securities Act.
About ProtoKinetix
ProtoKinetix, Inc. is a molecular biotechnology company that has
developed and patented a family of hyper stable, potent glycopeptides
(AAGP™) that dramatically enhance therapeutic results and reduce the
cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™
molecules, the Company is currently targeting the direct treatment of
diseases that have a major inflammatory component.
This press release shall not constitute an offer of securities in the
United States or any other jurisdiction. The securities that may
be issued pursuant to this press release are not currently qualified by
prospectus or registered under the U.S. Securities Act of 1933, as
amended (the “Securities Act”), or the laws of any state, and may not be
offered or sold in the United States, or to, or for the account or
benefit of United States persons (as defined in Regulation S under the
Securities Act) or persons in the United States absent registration or
an applicable exemption from the registration requirements. The
securities are subject to resale restrictions under applicable
securities laws.
Clarence E. Smith – President and CEO
Copyright Business Wire 2015